Selection/NN
and/CC
long-term/JJ
persistence/NN
of/IN
reactive/JJ
CTL/NN
clones/NNS
during/IN
an/DT
EBV/NN
chronic/JJ
response/NN
are/VBP
determined/VBN
by/IN
avidity/NN
,/,
CD8/NN
variable/JJ
contribution/NN
compensating/VBG
for/IN
differences/NNS
in/IN
TCR/NN
affinities/NNS
./.

Recent/JJ
studies/NNS
have/VBP
suggested/VBN
that/IN
the/DT
diversity/NN
of/IN
TCR/NN
repertoire/NN
after/IN
primary/JJ
immunization/NN
is/VBZ
conserved/VBN
in/IN
memory/NN
T/NN
cells/NNS
and/CC
that/IN
a/DT
progressive/JJ
narrowing/NN
of/IN
this/DT
repertoire/NN
may/MD
take/VB
place/NN
during/IN
recall/NN
infections/NNS
./.
=====
It/PRP
now/RB
remains/VBZ
to/TO
be/VB
investigated/VBN
which/WDT
parameters/NNS
determine/VBP
the/DT
repertoire/NN
of/IN
the/DT
memory/NN
response/NN
and/CC
possibly/RB
restrict/VB
its/PRP$
diversity/NN
after/IN
subsequent/JJ
antigenic/JJ
challenges/NNS
./.
=====
To/TO
address/VB
this/DT
question/NN
,/,
we/PRP
took/VBD
advantage/NN
of/IN
a/DT
panel/NN
of/IN
CD8+/JJ
T/NN
cell/NN
clones/NNS
from/IN
the/DT
joint/NN
of/IN
a/DT
rheumatoid/JJ
arthritis/NN
patient/NN
and/CC
selected/VBD
for/IN
their/PRP$
reactivity/NN
against/IN
a/DT
single/JJ
MHC/peptide/NN
complex/NN
./.
=====
Characterization/NN
of/IN
both/DT
TCR/NN
chains/NNS
documented/VBD
a/DT
great/JJ
diversity/NN
among/IN
those/DT
clones/NNS
and/CC
the/DT
persistence/NN
of/IN
clonotypes/NNS
over/IN
a/DT
2-yr/JJ
period/NN
./.
=====
Strikingly/RB
,/,
despite/IN
the/DT
observed/VBN
repertoire/NN
heterogeneity/NN
,/,
all/DT
clones/NNS
displayed/VBD
a/DT
narrow/JJ
range/NN
of/IN
MHC/peptide/NN
density/NN
requirements/NNS
in/IN
cytotoxicity/NN
assays/NNS
(/(
ED50/NN
between/IN
9/CD
and/CC
36/CD
nM/NN
)/)
./.
=====
TCR/NN
affinities/NNS
were/VBD
then/RB
indirectly/RB
estimated/VBN
by/IN
blocking/VBG
CD8/NN
interaction/NN
with/IN
an/DT
anti-CD8/JJ
mAb/NN
./.
=====
We/PRP
found/VBD
a/DT
wide/JJ
range/NN
of/IN
TCR/NN
affinities/NNS
among/IN
the/DT
different/JJ
clonotypes/NNS
that/WDT
segregated/VBD
with/IN
Vbeta/NN
usage/NN
./.
=====
We/PRP
thus/RB
propose/VBP
that/IN
during/IN
an/DT
in/FW
vivo/FW
chronic/JJ
response/NN
,/,
a/DT
narrow/JJ
range/NN
of/IN
avidity/NN
of/IN
the/DT
TCR-CD8/NN
complex/NN
conditions/VBZ
long-term/JJ
clonotype/NN
persistence/NN
,/,
and/CC
that/IN
the/DT
level/NN
of/IN
CD8/NN
contribution/NN
is/VBZ
adjusted/VBN
to/TO
keep/VB
clonotypes/NNS
with/IN
variable/JJ
TCR/NN
affinities/NNS
within/IN
this/DT
avidity/NN
window/NN
./.